CLDN6 and ovarian cancer: Currently three clinical studies targeting CLDN6 are ongoing in ovarian cancer patients: a CLDN6 CAR (NCT04503278 (45)), CLDN6 bispecific T cell engager (NCT05317078 (46)) and CLDN6 CAR-NK (NCT05410717).